Ancient and modern anticonvulsants act synergistically in a KCNQ potassium channel binding pocket
暂无分享,去创建一个
[1] G. Abbott,et al. In silico re-engineering of a neurotransmitter to activate KCNQ potassium channels in an isoform-specific manner , 2019, Communications Biology.
[2] Rakesh K Patel,et al. Development and validation of a RP-HPLC method for the simultaneous determination of Embelin, Rottlerin and Ellagic acid in Vidangadi churna , 2012, Journal of pharmaceutical analysis.
[3] C. Rundfeldt. The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. , 1997, European journal of pharmacology.
[4] M. Spinella. Herbal Medicines and Epilepsy: The Potential for Benefit and Adverse Effects , 2001, Epilepsy & Behavior.
[5] A. R.,et al. The Useful Plants of West Tropical Africa , 1938, Nature.
[6] Geoffrey W. Abbott,et al. Direct neurotransmitter activation of voltage-gated potassium channels , 2018, Nature Communications.
[7] Thomas Friedrich,et al. Refinement of the Binding Site and Mode of Action of the Anticonvulsant Retigabine on KCNQ K+ Channels , 2009, Molecular Pharmacology.
[8] D. A. Brown,et al. Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells , 2003, The Journal of physiology.
[9] Michael Okpara,et al. GC-MS analysis for Structural Identification and Bioactive Compounds in Methanolic Leaf Extract of Mallotus oppositifolius , 2016 .
[10] R. Willette,et al. Mallotoxin Is a Novel Human Ether-a-go-go-Related Gene (hERG) Potassium Channel Activator , 2006, Journal of Pharmacology and Experimental Therapeutics.
[11] Gleb P. Tolstykh,et al. Determinants within the turret and pore-loop domains of KCNQ3 K+ channels governing functional activity. , 2008, Biophysical journal.
[12] E. Ernst,et al. Valerian for insomnia: a systematic review of randomized clinical trials. , 2000, Sleep medicine.
[13] R. Bergman,et al. Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine. , 2014, JAMA dermatology.
[14] S. Berkovic,et al. A potassium channel mutation in neonatal human epilepsy. , 1998, Science.
[15] Jeffrey J Bruno,et al. Herbal Use among US Elderly: 2002 National Health Interview Survey , 2005, The Annals of pharmacotherapy.
[16] Aurélien Grosdidier,et al. Fast docking using the CHARMM force field with EADock DSS , 2011, J. Comput. Chem..
[17] D. Strøbæk,et al. Anxiolytic Effects of Maxipost (BMS-204352) and Retigabine via Activation of Neuronal Kv7 Channels , 2005, Journal of Pharmacology and Experimental Therapeutics.
[18] G. Abbott. Biology of the KCNQ1 Potassium Channel , 2014 .
[19] J. Mikkelsen,et al. Retigabine: chemical synthesis to clinical application. , 2006, CNS drug reviews.
[20] R. MacKinnon,et al. Cryo-EM Structure of a KCNQ1/CaM Complex Reveals Insights into Congenital Long QT Syndrome , 2017, Cell.
[21] M. Toth,et al. KCNQ1, KCNE2, and Na+-Coupled Solute Transporters Form Reciprocally Regulating Complexes That Affect Neuronal Excitability , 2014, Science Signaling.
[22] M. Eadie. Could Valerian Have Been the First Anticonvulsant? , 2004, Epilepsia.
[23] Jimmy D Bell,et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism , 2014, Nature Communications.
[24] S. Burbidge,et al. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. , 2000, Molecular pharmacology.
[25] I. Fietze,et al. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. , 2000, Pharmacopsychiatry.
[26] F. Marks,et al. Rottlerin, a novel protein kinase inhibitor. , 1994, Biochemical and biophysical research communications.
[27] D. A. Brown,et al. Two Types of K+ Channel Subunit, Erg1 and KCNQ2/3, Contribute to the M-Like Current in a Mammalian Neuronal Cell , 1999, The Journal of Neuroscience.
[28] Olivier Michielin,et al. Defining and searching for structural motifs using DeepView/Swiss-PdbViewer , 2012, BMC Bioinformatics.
[29] T. Friedrich,et al. Molecular Determinants of KCNQ (Kv7) K+ Channel Sensitivity to the Anticonvulsant Retigabine , 2005, The Journal of Neuroscience.
[30] G. Abbott,et al. Cilantro leaf harbors a potent potassium channel–activating anticonvulsant , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[31] T. Jegla,et al. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. , 2000, Molecular pharmacology.
[32] D. A. Brown,et al. Activation of Expressed KCNQ Potassium Currents and Native Neuronal M-Type Potassium Currents by the Anti-Convulsant Drug Retigabine , 2001, The Journal of Neuroscience.
[33] W. Löscher,et al. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures , 1996, Epilepsy Research.
[34] E. Woode,et al. Enhancement of inhibitory neurotransmission and inhibition of excitatory mechanisms underlie the anticonvulsant effects of Mallotus oppositifolius , 2016, Journal of pharmacy & bioallied sciences.
[35] Mark Leppert,et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns , 1998, Nature Genetics.
[36] Aurélien Grosdidier,et al. SwissDock, a protein-small molecule docking web service based on EADock DSS , 2011, Nucleic Acids Res..
[37] B S Brown,et al. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. , 1998, Science.
[38] S. Meuth,et al. The Natural Plant Product Rottlerin Activates Kv7.1/KCNE1 Channels , 2016, Cellular Physiology and Biochemistry.
[39] R. Goel,et al. Mallotus philippinensis Muell. Arg (Euphorbiaceae): Ethnopharmacology and Phytochemistry Review , 2014, BioMed research international.
[40] H. White. Preclinical Development of Antiepileptic Drugs: Past, Present, and Future Directions , 2003, Epilepsia.
[41] E. Perucca,et al. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V) , 2001, Epilepsy Research.
[42] E. Woode,et al. Screening of Central Effects of the Leaves of Mallotus oppositifolius (Geiseler) Mull. Arg. in Mice , 2012 .
[43] Md. Rakib Hasan,et al. Analgesic and Anti-Inflammatory Activities of Leaf Extract of Mallotus repandus (Willd.) Muell. Arg. , 2014, BioMed research international.
[44] C. Rundfeldt,et al. D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. , 1996, European journal of pharmacology.
[45] P. Christophersen,et al. Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352. , 2002, European journal of pharmacology.
[46] A. D. Krikorian. A Modern Herbal. The Medicinal, Culinary, Cosmetic and Economic Properties, Cultivation and Folk-Lore of Herbs, Grasses, Fungi, Shrubs & Trees, with All Their Modern Scientific Uses; with a New Service Index. Volumes I and II.M. Grieve , C. F. Leyel , 1968 .
[47] G. Abbott,et al. KCNQ5 activation is a unifying molecular mechanism shared by genetically and culturally diverse botanical hypotensive folk medicines , 2019, Proceedings of the National Academy of Sciences.
[48] Alan E. Mark,et al. The GROMOS96 Manual and User Guide , 1996 .
[49] S. Marx,et al. Activation of the BK (SLO1) Potassium Channel by Mallotoxin* , 2005, Journal of Biological Chemistry.
[50] Robin J. Leach,et al. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family , 1998, Nature Genetics.
[51] H. Oryem-Origa,et al. Traditional herbal remedies used in the management of sexual impotence and erectile dysfunction in western Uganda. , 2005, African health sciences.
[52] B. Abou-Khalil,et al. Ezogabine skin discoloration is reversible after discontinuation , 2017, Epilepsy & Behavior Case Reports.
[53] J. Dalziel,et al. The useful plants of West Tropical Africa. , 1938 .
[54] D. Strøbæk,et al. KCNQ4 channel activation by BMS-204352 and retigabine , 2001, Neuropharmacology.